Emergent BioSolutions Reports Financial Results for First Quarter 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Emergent BioSolutions (EBS) Tops Q1 EPS by 41c; Guides Q2 Revs Lower
April 29, 2021 4:15 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of... More
